CD90 and CD133 have been demonstrated to possess the traits of CSCs in lung cancer cells, including clonosphere growth in serum-free medium containing EGF, rapid in vivo tumorigenicity (38), and resistance to chemoradiotherapy (39). This evidence concerns the gene PROM1 and lung cancer.